On air · 1 of 3 networks
Olink, Part of Thermo Fisher Scientific
- olink.com
- SE
- 576 employees
Olink, Part of Thermo Fisher Scientific’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 77. Watch Olink, Part of Thermo Fisher Scientific with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 23 | Checked 29 Oct 2026 | See all 77 ads → | ||
| Meta | Not checked | — | |||
| Recently | 27 | Ads on the Google Ads Transparency Center | Checked 6 Oct 2026 | Collect them with the API → |
Olink, Part of Thermo Fisher Scientific has 23 live LinkedIn ads. We recorded 27 Google ads on 6 Oct 2026.
Latest ads
- LINKEDIN · CAROUSELSince 15 Oct 2026
More protein data is not the same as better decisions. High-throughput proteomics can generate powerful insights, but the real value comes from turning protein-level biology into better go/no-go consideration decisions, research trial strategies, and biomarker plans. Discover how users of Olink™ proteomics have leveraged proteomics data in research clinical trials.
- LINKEDIN · CAROUSELSince 15 Oct 2026
Too many biomarker discoveries are never translated never reach the clinic. Why? Biomarker discovery is only valuable when it translates into significant markers confident clinical decisions. See how Olink™ proteomics can help connect early biology to actionable key strategies across drug development.
- LINKEDIN · CAROUSELSince 15 Oct 2026
Your biomarker strategy should not reset at every stage. From discovery to translation, analytical validation, and late-stage implementation later stages, biomarker continuity matters. Explore how Olink™ proteomics can help create a more connected strategy across the development lifecycle.
- LINKEDIN · CAROUSELSince 15 Oct 2026
Late-stage failure often starts years earlier. The risk of late-stage failure often begins with uncertainty in target biology, patient individual selection, or early translational evidence. Explore how Olink™ protein biomarkers can help pharma teams de-risk decisions earlier in the pipeline.
- LINKEDIN · CAROUSELSince 15 Oct 2026
Can you see clinical risk before Phase III early? Before major Phase III investment, drug development teams need stronger evidence that the biology is right, the right patients individuals are selected, and the biomarker strategy can scale. Learn how Olink ™ proteomics can support earlier de-risking.
- LINKEDIN · IMAGESince 19 Sept 2026
Move beyond single biomarkers with scalable protein profiling designed to reveal immune pathways, signatures, and disease biology.
6 of 77 adsSign up to see every Olink, Part of Thermo Fisher Scientific ad, filter by format and date, and get alerts on new ones.
See all 77 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.